Clinical Trials at Lehigh Valley Hospital - Muhlenberg
As of August 2026, 45 paid clinical trials are recruiting at Lehigh Valley Hospital - Muhlenberg, located at 2545 SCHOENERSVILLE RD, BEHAVIORAL HEALTH SCIENCE CENTER; FIRST FLOOR, BETHLEHEM, PA 18017, phone (484) 884-5690 in Bethlehem, Pennsylvania. Active studies at this site cover conditions such as Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 and Lung Non-Small Cell Carcinoma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
45 clinical trials at Lehigh Valley Hospital - Muhlenberg
·Clear filters·Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Family Communications After Genetic Testing
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Common conditions studied in Bethlehem
- Anatomic Stage II Breast Cancer AJCC v8 (3 active studies)
- Anatomic Stage IV Breast Cancer AJCC v8 (3 active studies)
- Lung Non-Small Cell Carcinoma (3 active studies)
- Stage IIIB Lung Cancer AJCC v8 (3 active studies)
- Stage IV Renal Cell Cancer AJCC v8 (3 active studies)
- Advanced Esophageal Adenocarcinoma (2 active studies)
Leading research sponsors in Bethlehem
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
- SWOG Cancer Research Network
- ECOG-ACRIN Cancer Research Group
- NRG Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Bethlehem?
There are approximately 99 recruiting clinical trials in Bethlehem, Pennsylvania listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Bethlehem pay participants?
Most recruiting trials in Bethlehem compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Bethlehem?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Bethlehem?
The most common conditions under active study in Bethlehem include Anatomic Stage II Breast Cancer AJCC v8 (3), Anatomic Stage IV Breast Cancer AJCC v8 (3), Lung Non-Small Cell Carcinoma (3), Stage IIIB Lung Cancer AJCC v8 (3), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Bethlehem?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Bethlehem on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Bethlehem?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Bethlehem?
Recruiting research sites in Bethlehem include Lehigh Valley Hospital - Muhlenberg, St. Luke's University Health Network, Saint Luke's University Hospital-Bethlehem Campus, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Bethlehem right now?
The largest active categories in Bethlehem are Cancer & tumors (53), Eye & vision (5), Cardiovascular (4). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Lehigh Valley Hospital - Muhlenberg?
Lehigh Valley Hospital - Muhlenberg is located at 2545 SCHOENERSVILLE RD, BEHAVIORAL HEALTH SCIENCE CENTER; FIRST FLOOR, BETHLEHEM, PA 18017. Use the Google Maps link in the intro above to get directions.
How do I contact Lehigh Valley Hospital - Muhlenberg?
You can reach Lehigh Valley Hospital - Muhlenberg by phone at (484) 884-5690. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.